Press Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses

The European Commission has approved Sanofi's Cenrifki (tolebrutinib) for treating secondary progressive multiple sclerosis without relapses, marking the first disability-targeting therapy for this condition. The approval is based on the HERCULES phase 3 study demonstrating significant delay in disability progression. However, the drug carries identified safety risks including drug-induced liver injury, requiring strict liver monitoring.